

Optimizing Patient Outcomes: Collaborative Perspectives in Oncology



Keep pace with rapid advances in cancer treatment.

Stay informed about the latest evidence-based updates on cancer therapies, safety, and side effect management – empowering interprofessional teams to deliver exceptional care.

LIVE WEBINAR



**Thursday, November 12, 2026
10:00 – 11:00 AM EDT**

REGISTER

<https://education.nccn.org/node/98860>

AVAILABLE CREDIT

- 1.0 AAPA Category 1 CME credit
- 1.0 ACPE contact hour
- 1.0 AMA PRA Category 1 Credit™
- 1.0 ANCC contact hour
- 1.0 ANCC pharmacology contact hour
- 1.0 Participation

OVERVIEW

With the addition of several new agents for late relapsed/refractory multiple myeloma, it is important for the medical team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions. It is also crucial to understand the toxicities associated with these agents and deliver proper patient education.

Precision Immune Targeting: The Rise of Bispecifics in Multiple Myeloma



Tyler Sandahl
PharmD, RPh, BCOP
*Mayo Clinic
Comprehensive Cancer Center*

LEARNING OBJECTIVES

- Describe the need for newer therapies in the setting of late (after 4 or more prior lines of therapy) relapsed/refractory multiple myeloma.
- Discuss pivotal trials surrounding the FDA approval of bispecific antibodies for the treatment of late (after 4 or more prior lines of therapy) relapsed/refractory multiple myeloma.
- Identify key patient counseling and monitoring parameters for bispecific antibodies when used for the treatment of late (after 4 or more prior lines of therapy) relapsed/refractory multiple myeloma.

TARGET AUDIENCE

This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates and other health care professionals who treat patients with cancer.